What is Palatin Technologies's market cap?

Palatin Technologies (PTN) has a market capitalization of $18.7M and trades on AMEX.

Who are Palatin Technologies's competitors?

Palatin Technologies's key competitors include Rhythm Pharmaceuticals, Novo Nordisk, Eli Lilly, and others. These companies compete in similar markets and product categories.

Who does Palatin Technologies partner with?

Palatin Technologies's notable partners include Boehringer Ingelheim, Cosette Pharmaceuticals, Eli Lilly.

Where is Palatin Technologies headquartered?

Palatin Technologies is headquartered in United States of America and employs approximately 33 people. It has been publicly traded since 1993.

Palatin Technologies

PTN

Palatin Technologies is a biopharmaceutical company focused on developing first-in-class therapeutics that modulate the melanocortin receptor system.

Market cap

$18.66M-20.6%

Table of contents

Earnings

Q1 2026 report

May 13, 2026

Revenue$3.9MBeat by $2.6M EPS-$0.37Beat by $0.87

Read the full report

Next report

Sep 2, 2026 (in 2 months)

Revenue estimate$1.5M

EPS estimate-$1.20

Competitors

By market cap

Eli Lilly$1.09T+56.4%

AbbVie$441.54B+33.2%

Pfizer$138.21B-3.7%

Protagonist Therapeutics$8.9B+186%

Rhythm Pharmaceuticals, Inc.$7.9B+87.5%

Viking Therapeutics$4.8B+54.6%

Palatin Technologies$18.7M—

Alaunos Therapeutics$5.1M-39.7%

By revenue growth

Rhythm Pharmaceuticals, Inc.+58.7%

Eli Lilly+47.4%

AbbVie+9.5%

Pfizer+1.4%

Protagonist Therapeutics-64.4%

By net margin

Eli Lilly34.99%+12.3pp

Pfizer15.65%+6.3pp

AbbVie5.79%-1.5pp

Rhythm Pharmaceuticals, Inc.-93.33%+29.9pp

Protagonist Therapeutics-154.88%-182pp

Profile

Palatin Technologies is a biopharmaceutical company focused on developing first-in-class therapeutics that modulate the melanocortin receptor system. The company leverages a rational drug design approach to create peptides and small molecules targeting diseases with significant unmet medical needs, particularly in obesity and inflammatory conditions. Its business strategy centers on advancing internal candidates through clinical milestones and establishing strategic marketing collaborations with industry leaders.

Competitive position

A specialized developer of melanocortin-based therapeutics with a leading clinical-stage pipeline in MC4R and MC1R agonism.

GeographiesUnited States, Global

Customer segmentsPharmaceutical companies, Patients with metabolic disorders, Patients with inflammatory diseases

Business modelR&D focused, Licensing and Royalties, Collaborative Development

SuppliersContract Research Organizations (CROs), Contract Manufacturing Organizations (CMOs), Specialized peptide manufacturers, Academic research institutions

CustomersLarge pharmaceutical companies, Specialty biopharmaceutical firms, Healthcare providers, Patients

CountryUnited States of America

Listed1993

Employees33.0

CEOCarl Spana

SectorHealthcare

IndustryBiotechnology

Websitepalatin.com

FilingsSEC EDGAR

Questions, answered.

What is Palatin Technologies's market cap?: Palatin Technologies (PTN) has a market capitalization of $18.7M and trades on AMEX.
Who are Palatin Technologies's competitors?: Palatin Technologies's key competitors include Rhythm Pharmaceuticals, Novo Nordisk, Eli Lilly, and others. These companies compete in similar markets and product categories.
Who does Palatin Technologies partner with?: Palatin Technologies's notable partners include Boehringer Ingelheim, Cosette Pharmaceuticals, Eli Lilly.
Where is Palatin Technologies headquartered?: Palatin Technologies is headquartered in United States of America and employs approximately 33 people. It has been publicly traded since 1993.